Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study
Lønne, P. I.
Gambacorta, M. A.
Guren, M. G.
Mohamed, A. A.
Spindler, K. G.
van Triest, B.
Appelt, A. L.
AffiliationLeeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
MetadataShow full item record
AbstractBackground: Anal cancer is a rare cancer with rising incidence. Despite the relatively good outcomes conferred by state-of-the-art chemoradiotherapy, further improving disease control and reducing toxicity has proven challenging. Developing and validating prognostic models using routinely collected data may provide new insights for treatment development and selection. However, due to the rarity of the cancer, it can be difficult to obtain sufficient data, especially from single centres, to develop and validate robust models. Moreover, multi-centre model development is hampered by ethical barriers and data protection regulations that often limit accessibility to patient data. Distributed (or federated) learning allows models to be developed using data from multiple centres without any individual-level patient data leaving the originating centre, therefore preserving patient data privacy. This work builds on the proof-of-concept three-centre atomCAT1 study and describes the protocol for the multi-centre atomCAT2 study, which aims to develop and validate robust prognostic models for three clinically important outcomes in anal cancer following chemoradiotherapy. Methods: This is a retrospective multi-centre cohort study, investigating overall survival, locoregional control and freedom from distant metastasis after primary chemoradiotherapy for anal squamous cell carcinoma. Patient data will be extracted and organised at each participating radiotherapy centre (n = 18). Candidate prognostic factors have been identified through literature review and expert opinion. Summary statistics will be calculated and exchanged between centres prior to modelling. The primary analysis will involve developing and validating Cox proportional hazards models across centres for each outcome through distributed learning. Outcomes at specific timepoints of interest and factor effect estimates will be reported, allowing for outcome prediction for future patients. Discussion: The atomCAT2 study will analyse one of the largest available cross-institutional cohorts of patients with anal cancer treated with chemoradiotherapy. The analysis aims to provide information on current international clinical practice outcomes and may aid the personalisation and design of future anal cancer clinical trials through contributing to a better understanding of patient risk stratification.
CitationTheophanous S, Lønne PI, Choudhury A, Berbee M, Dekker A, Dennis K, et al. Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study. Diagnostic and prognostic research. 2022 Aug 4;6(1):14. PubMed PMID: 35922837. Pubmed Central PMCID: PMC9351222. Epub 2022/08/04. eng.
JournalDiagnostic and Prognostic Research
- Infrastructure platform for privacy-preserving distributed machine learning development of computer-assisted theragnostics in cancer.
- Authors: Field M, Thwaites DI, Carolan M, Delaney GP, Lehmann J, Sykes J, Vinod S, Holloway L
- Issue date: 2022 Aug 30
- Open-source distributed learning validation for a larynx cancer survival model following radiotherapy.
- Authors: Hansen CR, Price G, Field M, Sarup N, Zukauskaite R, Johansen J, Eriksen JG, Aly F, McPartlin A, Holloway L, Thwaites D, Brink C
- Issue date: 2022 Aug
- SurvMaximin: Robust federated approach to transporting survival risk prediction models.
- Authors: Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, Consortium for Clinical Characterization of COVID-19 by EHR 4CE.
- Issue date: 2022 Aug 23